227 related articles for article (PubMed ID: 31503425)
1. Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates.
De Bastiani MA; Klamt F
Cancer Med; 2019 Nov; 8(15):6717-6729. PubMed ID: 31503425
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates.
Vargas DM; De Bastiani MA; Zimmer ER; Klamt F
Alzheimers Res Ther; 2018 Jun; 10(1):59. PubMed ID: 29935546
[TBL] [Abstract][Full Text] [Related]
3. Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma.
Hu W; Wang G; Chen Y; Yarmus LB; Liu B; Wan Y
Aging (Albany NY); 2020 Aug; 12(16):16514-16538. PubMed ID: 32855362
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of COVID-19 transcriptional signatures between clinical samples and preclinical cell models in the search for disease master regulators and drug repositioning candidates.
Chapola H; de Bastiani MA; Duarte MM; Freitas MB; Schuster JS; de Vargas DM; Klamt F
Virus Res; 2023 Mar; 326():199053. PubMed ID: 36709793
[TBL] [Abstract][Full Text] [Related]
5. Master Regulators Connectivity Map: A Transcription Factors-Centered Approach to Drug Repositioning.
De Bastiani MA; Pfaffenseller B; Klamt F
Front Pharmacol; 2018; 9():697. PubMed ID: 30034338
[TBL] [Abstract][Full Text] [Related]
6. Identification of target gene and prognostic evaluation for lung adenocarcinoma using gene expression meta-analysis, network analysis and neural network algorithms.
Selvaraj G; Kaliamurthi S; Kaushik AC; Khan A; Wei YK; Cho WC; Gu K; Wei DQ
J Biomed Inform; 2018 Oct; 86():120-134. PubMed ID: 30195659
[TBL] [Abstract][Full Text] [Related]
7. Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
Lv Z; Lei T
BMC Cancer; 2020 Jan; 20(1):56. PubMed ID: 31987030
[TBL] [Abstract][Full Text] [Related]
8. Discovery of drug targets and therapeutic agents based on drug repositioning to treat lung adenocarcinoma.
Graves OK; Kim W; Özcan M; Ashraf S; Turkez H; Yuan M; Zhang C; Mardinoglu A; Li X
Biomed Pharmacother; 2023 May; 161():114486. PubMed ID: 36906970
[TBL] [Abstract][Full Text] [Related]
9. Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis.
MotieGhader H; Tabrizi-Nezhadi P; Deldar Abad Paskeh M; Baradaran B; Mokhtarzadeh A; Hashemi M; Lanjanian H; Jazayeri SM; Maleki M; Khodadadi E; Nematzadeh S; Kiani F; Maghsoudloo M; Masoudi-Nejad A
Sci Rep; 2022 Jun; 12(1):9417. PubMed ID: 35676421
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis reveals candidate genes and transcription factors in lung adenocarcinoma.
Chen B; Gao S; Ji C; Song G
Mol Med Rep; 2017 Dec; 16(6):8371-8379. PubMed ID: 28983631
[TBL] [Abstract][Full Text] [Related]
11. Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition.
Chang H; Liu Y; Xue M; Liu H; Du S; Zhang L; Wang P
Nucleic Acids Res; 2016 Apr; 44(6):2514-27. PubMed ID: 26926107
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
[TBL] [Abstract][Full Text] [Related]
13. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
14. Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas.
Ciribilli Y; Singh P; Spanel R; Inga A; Borlak J
Oncotarget; 2015 Oct; 6(31):31569-92. PubMed ID: 26427040
[TBL] [Abstract][Full Text] [Related]
15. Identification of the targets of hematoporphyrin derivative in lung adenocarcinoma using integrated network analysis.
Yin H; Yu Y
Biol Res; 2019 Feb; 52(1):4. PubMed ID: 30717818
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.
Vargas DM; De Bastiani MA; Parsons RB; Klamt F
Mol Neurobiol; 2021 Apr; 58(4):1517-1534. PubMed ID: 33211252
[TBL] [Abstract][Full Text] [Related]
17. Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis.
Rahman MR; Islam T; Gov E; Turanli B; Gulfidan G; Shahjaman M; Banu NA; Mollah MNH; Arga KY; Moni MA
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30658502
[TBL] [Abstract][Full Text] [Related]
18. Systems biology approach identifies key regulators and the interplay between miRNAs and transcription factors for pathological cardiac hypertrophy.
Recamonde-Mendoza M; Werhli AV; Biolo A
Gene; 2019 May; 698():157-169. PubMed ID: 30844478
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.
Wu CH; Hwang MJ
Cancer Med; 2019 Oct; 8(13):5850-5861. PubMed ID: 31407494
[TBL] [Abstract][Full Text] [Related]
20. Drug repurposing based on differentially expressed genes suggests drug combinations with possible synergistic effects in treatment of lung adenocarcinoma.
Yesharim L; Teimourian S
Cancer Biol Ther; 2023 Dec; 24(1):2253586. PubMed ID: 37710391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
